| Miao Zhang,Jianing qiu,Shuxian Qu,Yaling Han,Zhaozhe Liu,xiaodong xie. The clinical observation of neoadjuvant chemotherapy in locally advanced breast cancer with DX regimen. Oncol Transl Med, 2014, 13: 515-517. |
| The clinical observation of neoadjuvant chemotherapy in locally advanced breast cancer with DX regimen |
| Received:September 19, 2014 Revised:November 03, 2014 |
| View Full Text View/Add Comment Download reader |
| KeyWord:breast cancer; neoadjuvant chemotherapy; docetaxel; capecitabine |
| Author Name | Affiliation | Department | | Miao Zhang | Graduate School, Dalian Medical University, Dalian 116044, China | Graduate School, Dalian Medical University, Dalian 116044, China | | Jianing qiu | Graduate School, Dalian Medical University, Dalian 116044, China | Graduate School, Dalian Medical University, Dalian 116044, China | | Shuxian Qu | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | | | Yaling Han | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | | | Zhaozhe Liu | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | | | xiaodong xie | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China |
|
| Hits: 7659 |
| Download times: 8681 |
| Abstract: |
| Objective: The recent clinical curative effect and adverse events of docetaxel and capecitabine (DX) of neoadjuvant chemotherapy in patients with locally advanced breast cancer was discussed. Methods: The data of 72 cases of neoadjuvant chemotherapy (DX) in locally advanced breast cancer after 4 cycles were retrospectively analyzed. Docetaxel 75 mg/m2 by infusion 1 h on d1, capecitabine 2000 mg/m2 by oral for twice daily on d1–14, 21 days was a cycle. Results: All 72 patients were assessed for efficacy and adverse events. The total effective rate was 80.5% (58/72), including pathological complete response (pCR) was 7 (9.7%), clinical complete remission (cCR) was 15(20.8%), clinical partial response (PR) was 43 (59.7%), stable disease (SD) was 8 (11.1%) and progressive disease (PD) was 6 (8.3%). The main adverse events were gastrointestinal reactions and bone marrow suppression. The 3 to 4 degrees of adverse reactions including granulocytopenia in 7 patients (20.6%), hand-foot syndrome in 6 patients (15.2%). Conclusion: The DX regimen provide a favorable efficacy and safety profile in patients with locally advanced breast cancer for neoadjuvant chemotherapy. |
| Close |
|
|
|